Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone(The University of Texas MD Anderson Cancer Center), William N. William(The University of Texas MD Anderson Cancer Center), Annikka Weissferdt(The University of Texas MD Anderson Cancer Center), Cheuk Hong Leung(The University of Texas MD Anderson Cancer Center), Heather Lin(The University of Texas MD Anderson Cancer Center), Apar Pataer(The University of Texas MD Anderson Cancer Center), Myrna C. B. Godoy(The University of Texas MD Anderson Cancer Center), Brett W. Carter(The University of Texas MD Anderson Cancer Center), Lorenzo Federico(The University of Texas MD Anderson Cancer Center), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), M.A. Wadud Khan(The University of Texas MD Anderson Cancer Center), Hitoshi Dejima(The University of Texas MD Anderson Cancer Center), Alejandro Francisco‐Cruz(The University of Texas MD Anderson Cancer Center), Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Hai T. Tran(The University of Texas MD Anderson Cancer Center), Neda Kalhor(The University of Texas MD Anderson Cancer Center), Frank V. Fossella(The University of Texas MD Anderson Cancer Center), Frank E. Mott(The University of Texas MD Anderson Cancer Center), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), George Blumenschein(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Jonathan M. Kurie(The University of Texas MD Anderson Cancer Center), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Bonnie S. Glisson(The University of Texas MD Anderson Cancer Center), Lauren A. Byers(The University of Texas MD Anderson Cancer Center), Yasir Y. Elamin(The University of Texas MD Anderson Cancer Center), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), David C. Rice(The University of Texas MD Anderson Cancer Center), Garrett L. Walsh(The University of Texas MD Anderson Cancer Center), Wayne L. Hofstetter(The University of Texas MD Anderson Cancer Center), Jack A. Roth(The University of Texas MD Anderson Cancer Center), Mara B. Antonoff(The University of Texas MD Anderson Cancer Center), Humam Kadara(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(The University of Texas MD Anderson Cancer Center), Nadim J. Ajami(The University of Texas MD Anderson Cancer Center), Robert R. Jenq(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Stephen G. Swisher(The University of Texas MD Anderson Cancer Center), J. Jack Lee(The University of Texas MD Anderson Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Boris Sepesi(The University of Texas MD Anderson Cancer Center)
Cited by 599Open Access